Pre-Made Denileukin Diftitox Biosimilar, Fusion Protein targeting IL1RL2 fused with human IL2 (interleukin 2, IL-2): Recombinant therapeutic protein targeting IL-1Rrp2/IL-36R/IL1R-rp2/IL1RRP2 for drug discovery and mechanism of action (MOA) research

Pre-Made Denileukin Diftitox Biosimilar, Fusion Protein targeting IL1RL2 fused with human IL2 (interleukin 2, IL-2): Recombinant therapeutic protein targeting IL-1Rrp2/IL-36R/IL1R-rp2/IL1RRP2 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining interleukin-2 and diphtheria toxin. Denileukin diftitox could bind to interleukin-2 receptors[1] and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some leukemias and lymphomas, malignant cells express these receptors, so denileukin diftitox can target these.

Denileukin diftitox is a recombinant cytotoxic protein based on a combination of diphtheria toxin fragments and interleukin-2 used to treat cutaneous T-cell lymphoma by targeting the interleukin-2 receptor. Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.